Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

The Second Circuit revived an antitrust case Wednesday against AstraZeneca Plc and three other pharmaceutical firms, saying ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Just days after telling AstraZeneca how proud he was at its $50 billion investment strategy for the US, President Donald ...

The Department of Health and Human Services (HHS) has announced a plan to end mRNA vaccine work funded by the Biomedical ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

RSV typically causes mild, cold-like symptoms but can be serious, particularly in infants and older adults. AstraZeneca’s ADR was down 0.6% on Monday, while Sanofi’s ADR was up 0.2%.

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new facility in Virginia.